Complex Civil Litigation Law Firm

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Immutep To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Immutep between March 24, 2025 and March 12, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP) and reminds investors of the July 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. particularly following positive top-line results from Immutep’s prior TACTI-002 and INSIGHT-003 studies. Further, defendants announced in a Form-K filed with the SEC in January 30, 2026, that the trial was exhibiting “strong operational progress” and the planned interim futility analysis remained “on track for the first quarter of 2026.” In truth, Immutep was aware of or was reckless, based on its access to internal clinical data, analyses, and reports concerning the TACTI-004 trial and its planned interim futility evaluation, that then-existing information materially increased the risk that the study would fail to meet its primary efficacy and/or safety endpoints. Lead Plaintiff Deadline: July 6, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.

If you purchased or acquired securities in FS KKR Capital between May 8, 2024 and February 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FS KKR Capital Corp. (“FS KKR Capital” or the “Company”) (NYSE: FSK) and reminds investors of the July 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company overstated the effectiveness of its portfolio restructuring efforts for its nonaccrual companies; (2) the Company overstated the valuation of its portfolio investments and/or overstated the effectiveness of the Company’s portfolio valuation process; (3) the Company overstated the durability of its quarterly distribution strategy; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Lead Plaintiff Deadline: July 3, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In POET Technologies To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in POET Technologies between April 1, 2026 and 08:57 AM EST on April 27, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against POET Technologies, Inc. (“POET Technologies” or the “Company”) (NASDAQ: POET) and reminds investors of the June 29, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) POET Technologies misrepresented its tax status due to it likely being deemed a passive foreign investment company (or “PFIC”) under U.S. tax laws which, if not properly reported by each U.S. stockholder, would have negative tax implications for those U.S. stockholders; (2) the foregoing tax issue would, if discovered, make POET Technologies a less attractive investment than it would otherwise be, thus threatening POET Technologies’ valuation; (3) Defendant Thomas Mika, despite affirming that he was not violating a non-disclosure agreement, in fact violated a business agreement by speaking about POET Technologies’ business agreements in a public interview, thus endangering POET Technologies’ business prospects, and (4) as a result, defendants’ statements about POET Technologies’ business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. Lead Plaintiff Deadline: June 29, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In SES AI To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in SES AI between January 29, 2025 and March 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against SES AI Corporation (“SES AI” or the “Company”) (NYSE: SES) and reminds investors of the June 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) SES AI overstated its business prospects by materially overstating the expected results that could be achieved by deals with companies that have limited or no operations; (2) SES AI created an appearance of revenue by purchasing services in exchange for purchases of Molecular Universe; (3) Contrary to its positive statements regarding growth prospects, SES AI was affected by material logistics constraints in the fourth quarter of 2025 which would materially affect Q4 2025 revenues; (4) the foregoing called into question SES AI’s growth prospects for 2026, which were confirmed due to lower-than expected 2026 revenue guidance; and (5) as a result, defendants’ statements about SES AI’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. Lead Plaintiff Deadline: June 26, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.